{"entity":{"id":"quincy-chu","kind":"person","name":"Quincy Chu","aka":[],"tldr":"Edmonton oncologist who was lead author of KEYNOTE-483 (CCTG IND.227), the trial that showed adding pembrolizumab to chemotherapy lengthens survival in pleural mesothelioma.","summary":"Quincy Chu is a medical oncologist at the Cross Cancer Institute in Edmonton and a thoracic disease site leader in the Canadian Cancer Trials Group. He was first author of the 2023 Lancet report of IND.227/KEYNOTE-483, the international phase 3 trial in which pembrolizumab plus platinum-pemetrexed chemotherapy improved overall survival compared with chemotherapy alone in untreated unresectable pleural mesothelioma, leading to the combination's approval.","asOf":"2026-09-18","links":[],"tags":["mesothelioma","immunotherapy","trialist"],"related":[],"cancers":["pleural-mesothelioma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["cancer-care-alberta"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-keynote-483-lancet-2023"],"journals":[],"dependsOn":[],"notes":[],"role":"Medical oncologist, Cross Cancer Institute and University of Alberta, Edmonton","institutionId":"cancer-care-alberta","specialisms":["Mesothelioma","Lung cancer","Canadian Cancer Trials Group studies"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Chu%5BAuthor%5D"}],"papers":[]},"route":"/people/quincy-chu/","neighbours":{"cancer":[{"id":"pleural-mesothelioma","kind":"cancer","name":"Pleural mesothelioma","route":"/cancers/pleural-mesothelioma/"}],"institution":[{"id":"cancer-care-alberta","kind":"institution","name":"Cancer Care Alberta (Alberta Health Services)","route":"/institutions/cancer-care-alberta/"}],"paper":[{"id":"paper-keynote-483-lancet-2023","kind":"paper","name":"KEYNOTE-483 (CCTG IND.227): pembrolizumab plus chemotherapy versus chemotherapy in untreated pleural mesothelioma","route":"/key-papers/paper-keynote-483-lancet-2023/"}]}}